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Abstract
Background: Intraoperative radiation therapy (IORT) is one of the methods used to deliver a
large single dose to the tumor tissue while reducing the exposure of normal surrounding tissue.
However, the usefulness of intraoperative electron therapy for malignant gliomas has not been
established.
Methods: During the period from 1987 to 1997, 32 patients with malignant gliomas were treated
with IORT. The histological diagnoses were anaplastic astrocytoma in 11 patients and glioblastoma
in 21 patients. Therapy consisted of surgical resection and intraoperative electron therapy using a
dose of 12–15 Gy (median, 15 Gy). The patients later underwent postoperative external radiation
therapy (EXRT) with a median total dose of 60 Gy. Each of the 32 patients treated with IORT was
randomly matched with patients who had been treated with postoperative EXRT alone (control).
Patients were matched according to histological grade, age, extent of tumor removal, and tumor
location.
Results: In the anaplastic astrocytoma group, the one-, two- and five-year survival rates were 81%,
51% and 15%, respectively in the IORT patients and 54%, 43% and 21%, respectively in the control
patients. In the glioblastoma group, one-, two- and five-year survival rates were 63%, 26% and 0%,
respectively in the IORT patients and 70%, 18% and 6%, respectively in the control patients. There
was no significant difference between survival rates in the IORT patients and control patients in
either the anaplastic astrocytoma group or glioblastoma group.
Conclusions: IORT dose not improve survival of patients with malignant gliomas compared to
that of patients who have received EXRT alone.
Backgroud
Surgery and radiotherapy have been used to treat malig-
nant gliomas for many years, but the prognosis of malig-
nant glioma patients has been remained unsatisfactory.
Since local recurrence rather than distant metastasis is the
main pattern of recurrence [1–3], improvement in the lo-
Published: 15 January 2002
BMC Cancer 2002, 2:1
Received: 13 April 2001
Accepted: 15 January 2002
This article is available from: http://www.biomedcentral.com/1471-2407/2/1
© 2002 Nemoto et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-
commercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact info@biomedcentral.comBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/1
Page 2 of 5
(page number not for citation purposes)
cal control rate may greatly improve the survival of pa-
tients with malignant gliomas. Increasing the total
radiation dose is one possible way of improving local con-
trol. However, damage to the normal brain tissue increas-
es with increase in total radiation dose [4].
Intraoperative radiation therapy (IORT) is one of the
methods used for delivering a large single dose to the tu-
mor tissue while reducing the exposure of normal sur-
rounding tissue. However, the usefulness of IORT for
malignant gliomas has not been established. In this retro-
spective case-control study, the results of treatment with
IORT and external radiation therapy (EXRT) for previous-
ly untreated malignant glioma patients were compared
with those EXRT alone.
Methods
From 1987 through 1997, 32 patients with previously un-
treated malignant gliomas were treated with IORT. Histo-
logical diagnoses were anaplastic astrocytoma (AA) in 11
patients and glioblastoma (GBM) in 21 patients. The de-
cision to use IORT was made by neurosurgeons and radi-
ation oncologists. IORT was not used for patients with
deep-seated tumors or infra-tentorial tumors. Moreover,
since there were only two linear accelerators in our hospi-
tal during the period 1982 to 1998, the use of a linear ac-
celerator for IORT was severely restricted and only a
limited number of patients could be treated with IORT.
Following as much tumor removal as possible, patients
were transferred from the operating room to the linac
room. Then cones of 4–8 cm in diameter attached to the
linac gantry were placed directly onto the tumor bed. The
energy of the electron beams ranged from 4 to 15 MeV de-
pending on the estimated tumor depth. The IORT dose
ranged from 12 to 15 Gy (median, 15 Gy; mean, 14.9 Gy).
The IORT dose was evaluated at the peak point.
Following IORT, all patients EXRT at a median total dose
of 60 Gy (mean dose, 57 Gy; range, 17–72 Gy). A 10 MV
X-ray generated by a linear accelerator was used for EXRT.
The clinical target volume was gross tumor (determined
by CT or MRI images postoperatively) with a 2-cm mar-
gin. The median time interval from IORT and start of
EXRT was 15 days (range, 9–41 days). Written informed
consent was obtained from all of the eligible patients.
Each of the 32 patients treated with IORT was randomly
matched with a malignant glioma patient treated with
EXRT alone from 1982 to 1997 (number of patients, 236).
Patients were matched according to histological grade (AA
or GBM), age (=<59 years old or >59 years old), extent of
tumor removal (total removal, subtotal removal or partial
removal, biopsy only), and tumor location. However, per-
formance status could not be used as a matching criterion
in many of the patients due to lack of clinical information.
The patients' characteristics are listed in Table 1: The treat-
ment characteristics are listed in Table 2.
The length of survival was measured from the time of sur-
gery until the patients died or until the time of final anal-
ysis. The last follow up examination was performed in
October 2000. The Kaplan-Meier method was used to cal-
culate the survival rate. The differences between survival
curves were evaluated by the logrank test.
Results
The median survival times for AA patients and GBM pa-
tients were 24.7 months and 14.1 months, respectively.
The one-, two- and five-year survival rates in AA patients
were 67%, 52% and 19%, respectively, and those in GBM
patients were 67%, 22% and 6%, respectively (Fig. 1). The
difference between survival rates of AA patients and GBM
patients was statistically significant (p = 0.046).
In the AA group, the median survival times in IORT pa-
tients and control patients were 24.7 months and 33.6
months, respectively. The one, two, and five-year survival
rates in IORT patients were 81%, 51% and 15%, respec-
tively, and those in control patients were 54%, 43% and
21%, respectively. There was no significant difference be-
tween survival rates in the treatment groups (Fig. 2).
In the GBM group, the median survival time in IORT pa-
tients was 13.3 months and that in control patients was
14.6 months. The one-, two- and five-year survival rates in
Figure 1
Survival curves by histological diagnosis.
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IORT patients were 63%, 26% and 0%, respectively, and
those in control patients were and 70%, 18% and 6%, re-
spectively. The survival rate from 24 to 48 months was
better in IORT patients than in control patients, but the
difference was not statistically significant. The only pa-
tient who survived more than five years was in the control
group (Fig. 3).
There were no treatment-related deaths in the patients
who received IORT and in those who did not. In four
IORT patients and in one control patient, CT and MRI
findings suggested brain necrosis. However, differential
diagnosis of brain necrosis from tumor regrowth was dif-
ficult in these patients.
Discussion
Increasing the total radiation dose is the possible way to
improve the local control of malignant gliomas. A study
by Walker et al showed beneficial effect of dose escalation
up to 60 Gy [5]. On the other hand, Chang et al. reported
that there was no advantage of a radiation dose of 70 Gy
for 8–9 weeks over a dose of 60 Gy for 6–7 weeks [6].
Therefore, the standard radiation dose used for malignant
gliomas has been 60 Gy/6–7 weeks, and the usefulness of
dose escalation over 60 Gy for malignant glioma has been
controversial. On the other hand, since recurrences occur
from the initial tumor regions in most malignant gliomas
patients, attempts have been made to deliver a large dose
to the tumors while avoiding surrounding normal tissue
using IORT [7–9], brachytherapy [10,11], conformal radi-
ation therapy [12], particle radiation therapy [13], and ra-
diosurgery [14].
Several authors reported that IORT improved survival of
malignant glioma patients. Matsutani et al. treated 30
glioblastoma patients with IORT (mean dose,18.3 Gy)
combined with EXRT (mean dose, 58.5 Gy), and the me-
dian survival period and 2-year survival rate were 119
weeks and 61%, respectively, in their series [9]. Ortiz et al.
used IORT for malignant glioma patients and reported
that the overall 1-year survival rates were 67% for AA pa-
tients and 56% for GBM patients [8]. Fujiwara et al. used
IORT with EXRT for 20 previously untreated malignant
glioma patients. They reported that the survival of patients
who had undergone IORT was better than that of patients
who had been treated with EXRT alone. The median sur-
vival periods were 14 months for the patients who had
been treated with IORT and 10 months for the patients
who had been treated with EXRT alone [7].
However, we must be careful when comparing the results
of treatment with IORT with the results in controls, be-
cause IORT can not be used for patients with deep-seated
tumors, multifocal tumors, diffuse infiltrating tumors,
very large tumors, or infra-tentorial tumors. Therefore, it
is possible that the selection criteria of patients for IORT
greatly influence the treatment outcomes. In this study, a
matched-pair group of patients who had been treated with
EXRT alone was used for the control group to minimize
Figure 2
Survival of patients with anaplastic astrocytoma by use of
IORT.
Figure 3
Survival of patients with glioblastoma by use of IORT.
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confounding. As a result, there was no significant differ-
ence between survival rates of either AA or GBM patients
who had received IORT and those who had not.
In our series, the settings of cones in the linac room were
made by neurosurgeons and radiation oncologists, de-
pending on the findings at tumor removal. However, it
was difficult to determine the optimal position and direc-
tion of the cones in the linac room, because radiotherapy
planning based on CT and MRI images was impossible in
such situations. Therefore, the method of cone and pa-
tient setting in the linac room might have resulted in geo-
graphic errors and might have influenced the treatment
outcomes. In order to correct such possible setting errors,
intraoperative CT-based planning with a mobile CT and a
fixation device that is used for radiosurgery may be useful.
The usefulness of IORT should be tested again in a rand-
omized clinical trial after the establishment of radiothera-
py planning methods for IORT and a method to
reproduce the planned setting in the linac room.
Conclusions
IORT did not improve survival of malignant glioma pa-
tients compared to that of following conventional radia-
tion therapy alone.
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